Medical Policy



Subject: Cochlear Implants and Auditory Brainstem Implants
Document #: SURG.00014 Current Effective Date:    09/27/2017
Status: Revised Last Review Date:    08/03/2017

Description/Scope

This document addresses cochlear implants, auditory brainstem implants, and replacement or upgrade of speech processor and controller components. This document does not address replacement parts other than as specifically described below.

A single or multi-channel unilateral or bilateral cochlear implant is intended to restore a level of auditory sensation to an individual with bilateral severe to profound sensorineural hearing loss by means of electrical stimulation of the auditory nerve. A unilateral hybrid cochlear implant is intended to restore a level of auditory sensation to an individual with residual low-frequency hearing sensitivity and bilateral severe to profound sensorineural hearing loss.

An auditory brainstem implant is a device designed to restore some hearing in an individual with neurofibromatosis type 2 (NF-2) rendered deaf by the surgical removal of neurofibromas involving both auditory nerves.

Position Statement

I.  Cochlear Implants

Medically Necessary:

  1. Unilateral or bilateral implantation of a U.S. Food and Drug Administration (FDA) approved single or multi-channel cochlear implant is considered medically necessary in an individual with bilateral severe-to-profound pre- or postlingual hearing loss (sensorineural deafness), defined as a hearing threshold of pure tone average of 70 decibels or greater, when all of the following criteria are met:
    1. The individual, including those with hearing loss due to meningitis, has obtained limited benefit from conventional hearing aids; and
    2. The individual is free from lesions in the auditory nerve and acoustic areas of the central auditory pathway (nervous system); and
    3. The individual is free from otitis media or other active middle ear infections; and
    4. The individual* is able to participate in a post-cochlear implant rehabilitation program in order to achieve benefit from the cochlear implant device.
      *Note: For a young child, a parent or guardian may act as the surrogate for participation.
  2. Unilateral implantation of an FDA approved single or multi-channel cochlear implant is considered medically necessary for subsequent bilateral implantation (that is, sequential implantation) without retesting of hearing when the above criteria are met at the time of the initial (first) cochlear implantation.
  3. Upgrade to or replacement of an existing external speech processor, controller or speech processor and controller (integrated system) is considered medically necessary for an individual whose response to existing components is inadequate to the point of interfering with the activities of daily living or when components are no longer functional.
  4. Cochlear implantation with an FDA approved hybrid cochlear implant device (for example, Nucleus® Hybrid™ L24 Cochlear Implant System) is considered medically necessary in an individual 18 years of age and older with bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity (that is, able to hear low-frequency sounds) when all of the following preimplantation criteria are met:
    1. Limited benefit from appropriately fit bilateral hearing aids; and
    2. Normal to moderate hearing loss in the low-frequencies (that is, hearing thresholds no poorer than 60 decibels hearing level up to and including 500 hertz (averaged over 125, 250, and 500 hertz) in the ear selected for implantation; and
    3. Severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 hertz greater than or equal to 75 decibels hearing level) in the ear to be implanted; and
    4. Moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 hertz greater than or equal to 60 decibels hearing level) in the contralateral ear; and
    5. Preoperative speech perception scores as follows:
      1. Consonant-Nucleus-Consonant word recognition score from 10% to 60% in the ear to be implanted; and
      2. Consonant-Nucleus-Consonant word recognition score in the contralateral ear equal to or better than in the ear to be implanted, but not more than 80% in the best-aided condition; and
    6. Individual is free from lesions in the auditory nerve and acoustic areas of the central auditory pathway (nervous system); and 
    7. Individual is free from otitis media or other active middle ear infections; and
    8. Individual is able to participate in a post-hybrid cochlear implant rehabilitation program in order to achieve benefit from the hybrid cochlear implant device.

Not Medically Necessary:

Upgrade to or replacement of an existing external speech processor, controller or speech processor and controller (integrated system) is considered not medically necessary when the criteria specified above are not met or when requested for convenience or to upgrade to a newer technology when the current components remain functional.

Investigational and Not Medically Necessary:

A cochlear implant is considered investigational and not medically necessary for all other indications when the above criteria are not met, including but not limited to treatment of any of the following:

  1. Auditory neuropathy spectrum disorders; or
  2. Tinnitus in individuals who do not also have bilateral severe-to-profound hearing loss (sensorineural deafness); or
  3. Unilateral deafness.

II.  Auditory Brainstem Implants

Medically Necessary:

  1. An FDA-approved auditory brainstem implant is considered medically necessary in an individual when all of the following criteria are met:
    1. Is 12 years of age or older; and
    2. Diagnosed with neurofibromatosis type 2; and
    3. Is completely deaf as a result of bilateral neurofibromas of the auditory nerve.
  2. Upgrade to or replacement of an existing external sound processor, remote assistant or both components is considered medically necessary for an individual whose response to existing components is inadequate to the point of interfering with the activities of daily living or when components are no longer functional.

Not Medically Necessary:

Upgrade to or replacement of an existing external sound processor, remote assistant, or both components is considered not medically necessary when the criteria specified above are not met or when requested for convenience or to upgrade to a newer technology when the current components remain functional.

Investigational and Not Medically Necessary:

An auditory brainstem implant is considered investigational and not medically necessary for all other indications when the above criteria are not met.

Rationale

Single or Multi-Channel Cochlear Implants

Cochlear implants are recognized as an effective treatment of sensorineural deafness. While use of a unilateral cochlear implant in an individual with severe to profound hearing loss has become a standard clinical practice, bilateral implantation is less common. Evolution of cochlear implant devices has focused on minimizing the internally implanted electrodes, such that one device, the Nucleus® 24 (Cochlear Americas, Englewood, CO), received FDA approval (2000) for use in children 12 months of age and older. A review of the early peer-reviewed literature includes several reports on individuals with bilateral cochlear implants (Long, 2003; Muller, 2002; Schoen, 2005; Tyler, 2002; van Hoesel, 2002; van Hoesel, 2003). These early reports evaluated small numbers of individuals and provided limited outcome information. In these reports, most, but not all, individuals reported very slight to modest improvements in sound localization and speech intelligibility with bilateral cochlear implants, especially with noisy backgrounds, but not necessarily in quiet environments. When reported, the combined use of binaural stimulation improved hearing by only a few decibels or percentage points. This improvement appeared marginal, and may not outweigh the significant risks of a second implantation. In addition, similar binaural results can be achieved with a contralateral hearing aid, assuming the contralateral ear has speech recognition ability (Morera, 2005).

Subsequently, a number of prospective case series designed to assess whether bilateral cochlear implants could provide some of the benefits of binaural hearing were published in the peer-reviewed literature. These studies assessed the benefits of bilateral cochlear implants on sound localization and speech perception in both adults (Gantz, 2002; Laszig, 2004; Litovsky, 2004; Schoen, 2005; Verschuur, 2005), and, to a lesser extent, in children (Kuhn-Inacker, 2004; Litovsky, 2006). The largest and most complete of these case studies included a case series of 30 U.S. children with sequentially placed bilateral cochlear implants (Peters, 2007).

Bond and colleagues (2009b) authored a technology assessment in the United Kingdom (U.K.) to investigate the clinical and cost-effectiveness of unilateral cochlear implants (using or not using hearing aids), and bilateral cochlear implants compared with a single cochlear implant (unilateral or unilateral plus hearing aid) for severely to profoundly deaf children and adults. The clinical effectiveness review included 33 papers, of which 2 were randomized controlled trials (deaf children, n=1513; adults, n=1379). A total of 62 different outcome measures were evaluated and the overall evidence was of moderate to poor quality. All studies of children comparing one cochlear implant with non-technological support or an acoustic hearing aid reported gains on all outcome measures. Weak evidence showed greater gain from earlier implantation (prior to starting school). The strongest evidence for an advantage of bilateral implantation over unilateral implantation was for speech recognition in noisy conditions. A comparison of bilateral implants with unilateral cochlear implants plus an acoustic hearing aid was limited by small sample sizes and poor reporting. The authors concluded:

Unilateral cochlear implantation is safe and effective for adults and children and likely to be cost-effective in profoundly deaf adults and profoundly and prelingually deaf children. There are likely to be overall additional benefits from bilateral implantation, enabling children and adults to hold conversations more easily in social situations.

Bond and colleagues subsequently published two systematic reviews on the clinical and cost-effectiveness of unilateral cochlear implants, one review focusing on children (Bond, 2009a) and the other review focusing on adults (Bond, 2010). Both reviews were conducted with a literature search that identified 1580 titles and abstracts on cochlear implants. There was significant heterogeneity in design and outcomes that precluded meta-analysis in the review of unilateral pediatric cochlear implants; however, all studies reported that unilateral pediatric cochlear implants improved scores on all outcome measures. In the 2010 review, nine studies met the inclusion criteria for cochlear implantation in adults. The available studies were methodologically weak and too heterogeneous to perform a meta-analysis; however, the authors concluded there is sufficient, consistent evidence demonstrating positive benefits with unilateral cochlear implants in severely to profoundly hearing impaired adults when compared to acoustic hearing aids or no hearing support.

Lammers and colleagues (2014) summarized the evidence on the effectiveness of bilateral cochlear implantation compared with unilateral implantation among children with sensorineural hearing loss. A total of 21 studies evaluated bilateral implantation in children, with no randomized controlled trials identified. The authors were unable to perform pooled statistical analysis due to a limited number of studies, heterogeneity in outcomes and comparison groups and a high risk for bias in the studies. A "best-evidence synthesis" was performed, with results "…indicating the positive effect of the second implant for especially sound localization and possibly for preverbal communication and language development." One study demonstrated improvements in language development, although other studies found no significant improvements. The currently available evidence consists solely of cohort studies that compare a bilaterally implanted group with a unilaterally implanted control group, with only one study providing a clear description of matching techniques to reduce bias.

Cochlear Implantation in Adults with Bilateral Severe-to-Profound Hearing Loss

Gantz and colleagues (2002) evaluated bilateral cochlear implantation in 10 adults with severe to profound, postlingual hearing loss. These adults were evaluated for unilateral cochlear implants, found to have different duration of deafness and tone thresholds in each ear, and received bilateral cochlear implants in a single surgical procedure. Age of onset of deafness was not reported. Follow-up at 1 year showed significantly better performance for sound localization in all adults using bilateral versus unilateral implants. A total of 5 of the 10 adults showed better performance in speech perception in quiet and in noise. These findings without a study control group provided an initial indication that compared with unilateral cochlear implants, bilateral cochlear implants may allow significant improvement in sound localization and speech perception.

Litovsky and colleagues (2004) examined 14 adults with postlingual deafness and 3 adults with prelingual deafness who received bilateral cochlear implants. Sound localization and speech perception tests were completed 3 months after activation, with sound localization reported as significantly improved in 15 adults (88%) compared with monaural testing. Speech perception was improved in 6 adults (43%). Limitations of this study include the small sample size and duration of follow-up of only 3 months, which may have been insufficient to identify the scope and degree of benefit. Cause of deafness, participant selection criteria, and exclusion criteria were not reported. In a multicenter trial, Laszig and colleagues (2004) studied 37 postlingually deafened adults, 22 with simultaneously-implanted bilateral cochlear implants and 15 with sequentially-implanted cochlear implants. Serial auditory tests were carried out at 1, 3 and 6 months with each adult serving as his or her own control. Serial assessments of unilateral and bilateral listening performance on tests of speech comprehension and sound localization were performed. Mean speech perception performance scores at 6 months with the speech signal closest to the better ear and the noise signal closest to the poorer ear resulted in a mean unilateral (better ear) score of 62% and mean bilateral score of 70%. Although modest (8%), this bilateral listening advantage did reach statistical significance; however, during testing in a quiet environment, there was no difference in mean speech perception scores between the best ear monaural condition and binaural listening condition. The binaural localization ability was superior to monaural localization ability for all but 1 adult. Binaural localization was significantly superior to the monaural condition (p<0.0005), with localization error reduced by 38o compared with unilateral stimulation (88o compared to 50o ). The methods by which these adults were selected from tertiary referral centers with cochlear implant programs were not reported. All of the adults received the Nucleus 24 cochlear implant, but there was variation in the type of speech processor and speech coding strategy.

Schoen and colleagues (2005) retrospectively studied 12 adults with postlingual hearing loss who received bilateral cochlear implants in a single surgical procedure (n=3) or in two sequential procedures (n=9). A total of 11 adults were tested for sound localization at 3 months, with the location of sound source significantly improved to near normal accuracy. The study subjects were selected from a group of 14 adults bilaterally implanted in Wuerzburg, Germany prior to 2002. No other information is provided with regard to participant selection criteria for this case study.

Similar results were reported in a case series (n=20) of post-lingually deafened adults who participated in a U.K. multicenter trial (Verschuur, 2005). The adults were recruited from a group using either the Nucleus 24M® or 24K® cochlear implant with at least 9 months experience with using the second device. Additional criteria for inclusion in the study were duration of severe deafness no longer than 15 years in either ear, 30% speech recognition in the first ear, minimal benefit from a conventional hearing aid in the non-implanted ear, and a "high level of motivation for bilateral implantation." Mean duration of deafness was 9 years; mean gap between the first and second implant was 35 months. The adults were tested between 3 months and 9 months after initial tuning of the second device. This study suggested that bilateral cochlear implants provide significant improvement in sound localization ability compared with unilateral cochlear implants in all subjects regardless of sound source location. Mean localization error with bilateral implants was 24o compared with 67o for monaural implants and 2o for normal hearing controls. In this study, binaural sound localization performance was better than monaural performance for all subjects, for all stimulus types, and for different sound sources.

A multicenter prospective study by Litovsky and colleagues (2006) reported on 37 adults with post-linguistic bilateral hearing loss. Bilateral benefit (speech understanding in quiet and noise) was seen in 32 of the 34 individuals. The authors suggested that the three decibel improvement in signal to noise ratio noted in the study would result in an average improvement of 28% in speech understanding and that this improvement could be crucial. Questionnaire data indicated that bilateral users perceived their performance to be better than when using a single device. Ricketts and colleagues (2006) reported on 16 adults with similar postlinguistic bilateral hearing loss, finding a small but significant advantage with bilateral implants for speech recognition in noise. While a training effect was noted over time for a subset of adults followed up to 17 months, a consistent bilateral advantage was noted. Ramsden and colleagues (2005) studied 30 adults in England who received their second implant a mean of 3 years after the first. At 9 months, a significant (12.6%; p<0.001) binaural advantage was seen for speech and noise from the front. They were not able to predict if the second ear would be the better performer. Sequential implantation with long delays between ears resulted in poor second ear performance for some of their subjects. When viewed together, these small retrospective case studies of post-lingually deafened adults suggest that bilateral cochlear implantation may have the potential to improve sound localization in most adults and may improve speech perception in others when compared with unilateral implantation.

A technology assessment on the effectiveness of cochlear implants in adults completed by the Tufts Evidence-based Practice Center for the Agency for Health Care Research and Quality (AHRQ, 2011) examined 22 studies with 30 or more participants, concluding that while the studies reviewed were rated as poor-to-fair quality, unilateral cochlear implants are effective in adults with sensorineural hearing loss. Pre- and post-cochlear implant scores on multi-syllable tests and open-set sentence tests demonstrated significant gains in speech perception regardless of whether a contralateral hearing aid was used along with the cochlear implant. Additionally, the assessment found generic and disease-specific health-related quality of life improved with unilateral cochlear implants. The available evidence was insufficient to draw conclusions on improvements in open-set sentence test scores and any relationship between pre-implantation characteristics of individuals and outcomes (for example, age, duration of hearing impairment, Hearing in Noise Test [HINT] scores, and pre- or post-linguistic deafness). Gaylor and colleagues (2013) published an update to the 2011 AHRQ technology assessment evaluating the communication-related outcomes and health-related quality of life outcomes after unilateral or bilateral cochlear implantation in adults with sensorineural hearing loss. A total of 16 of 42 studies published through May 2012 evaluated use of unilateral cochlear implants. Most unilateral implant studies showed a statistically significant improvement in mean speech scores as measured by open-set sentence or multisyllable word tests; meta-analysis of 4 studies revealed a significant improvement in cochlear-implant relevant quality of life after unilateral implantation (standard mean difference: 1.71; 95% confidence interval [CI], 1.15 to 2.27). However, these studies varied in design, and there was considerable heterogeneity observed across studies.

In summary, studies of cochlear implants in adults with severe-to-profound hearing loss who only receive limited or no benefit from amplification with conventional hearing aids, show consistent improvement in speech reception (especially in noise) and in sound localization with bilateral devices. Studies also suggest that earlier implantation may be preferred. Based on these studies and several systematic reviews (Crathorne, 2012; van Schoonhoven, 2013) that provide additional evidence in support of unilateral and bilateral cochlear implantation, cochlear implants have been shown to provide sufficient benefit to improve net health outcomes in individuals with bilateral hearing loss.

Cochlear Implantation in Unilateral Deafness (with or without Tinnitus)

The evidence in the peer-reviewed literature is insufficient to permit conclusions concerning the effect of cochlear implantation for the treatment of unilateral hearing loss (single-sided deafness), including cochlear implants for tinnitus relief in individuals with unilateral deafness. The available evidence to support implantation as a treatment for individuals with tinnitus who do not also have bilateral profound or severe sensorineural hearing loss is limited and consists of a few observational studies with a small number of participants (Arts, 2012; van de Heyning, 2008).

Blasco and Redleaf (2014) published a systematic review and meta-analysis of studies evaluating cochlear implantation for improvement of tinnitus and speech comprehension in unilateral sudden deafness. In the pooled analysis of nine studies with 36 participants, subjective improvement in tinnitus occurred in 96% of 27 participants assessed, subjective improvement in speech understanding occurred in 100% of 16 participants assessed, and subjective improvement in sound localization occurred in 87% of 16 participants assessed. The meta-analyses demonstrated a high-degree of interstudy heterogeneity among a small study population. The authors suggest that additional study with follow-up of longer duration (> 24 months) is necessary to compare symptoms and performance between unilateral cochlear implantation and more traditional strategies for hearing rehabilitation.

Van Zon and colleagues (2015) published a systematic review of studies evaluating cochlear implantation for single-sided deafness or asymmetric hearing loss. A total of nine studies (n=112 subjects) were considered in the data review, but included no high-quality studies of cochlear implantation in this population. The authors were unable to pool the data for meta-analysis due to high between-study heterogeneity in participants (classification of hearing loss, duration of deafness, and the indication for cochlear implantation [hearing loss vs. tinnitus]), test conditions (pre-implant vs. post-implant), follow-up duration, and outcome measurements (that is, different test configurations, word tests, and/or questionnaires). The authors concluded the "current literature suggests important benefits of cochlear implantation in this population regarding sound localization, quality of life, and tinnitus. Although results for speech perception in noise are promising as well, varying results between studies were reported for this outcome."

Sladen and colleagues (2016) conducted a prospective repeated-measures study examining speech recognition and self-perceived health-related quality of life in a cohort of 20 adults and children who received a cochlear implant for unilateral hearing loss (> 6 months, but < 2 years). The etiology of the hearing loss was attributed to idiopathic sudden sensorineural hearing loss (n=15), otosclerosis (n=2), vestibular schwannoma (n=1), cholesteatoma (n=1), or bacterial sepsis (n=1). A total of 15 (75%) participants reached the 6-month post-activation point and were included in the final data analysis. A significant improvement in speech recognition in both quiet and noise was reported at the 6-month post-activation point. Consonant-Nucleus-Consonant (CNC) scores in quiet improved from 4.8% in the preoperative period to 42.3% a 6-months post-activation. However, limitations of this study exist, including the small sample size, comprised of predominantly younger adults with a short duration of reported hearing loss prior to implantation, and the short follow-up period. 

Sladen and colleagues (2017) retrospectively reviewed data (prospectively collected) of short-term outcomes for 23 adults and children with single-sided deafness from multiple etiologies (most frequently, sudden sensorineural hearing loss [n=12] and congenital conditions [n=3]) who received a cochlear implant. Participants had mild to severe sensorineural hearing loss with ≤ 40% CNC word recognition on the affected side and normal hearing in the nonimplanted ear. CNC word recognition improved significantly from pre-implantation to 3 months post-activation (p=0.001), but not between the 3-month and 6-month intervals in 13 of the 20 evaluable participants. There was no significant improvement in 8 participants from pre-implantation to 6 months post-activation for AzBio sentence understanding in noise (+ 5 decibels signal-to-noise). Twelve of the 13 participants who reported tinnitus prior to surgery reported subjective improvement after implantation. Limitations of this study include the small sample size with retrospectively collected data from a variable number of participants at the 3- and 6-month intervals; additionally, study outcomes were evaluated using separate and unique testing protocols at the two participating treatment centers. Finally, the heterogeneous study population comprised of children and adults with various hearing loss etiologies and duration of deafness limits drawing conclusions as to the net health benefit of cochlear implantation in individuals with unilateral sensorineural hearing loss.

In summary, the evidence for cochlear implantation for unilateral deafness, with or without tinnitus, consists primarily of non-randomized, retrospective studies and case series reporting varying results and a high-degree of interstudy heterogeneity among small study populations. Additional study is needed measuring long-term outcomes in order to establish the clinical utility of cochlear implantation as a treatment for unilateral deafness with or without tinnitus.

Cochlear Implantation in Pediatrics

Cochlear Implantation in Children 12 Months of Age and Older

The early peer-reviewed literature concerning the use of bilateral cochlear implants in children is limited. The first significant study of bilateral implants in children was reported by Kuhn-Inacker and colleagues (2004). This study described the auditory skills in a heterogeneous group of 32 children enrolled in a German cochlear rehabilitation program following the placement of bilateral cochlear implants. Age at first implant ranged from 8 months to 16 years, with age at second implant ranging from 1 year to 16 years. A total of 10 children had their second implant within 1 year following the first implant. Four children had simultaneous implants. A total of 16 children were postlingually implanted with the second ear after acquiring basic speech perception. Two children were prelingually deafened due to meningitis and 14 had limited speech perception when they received their second implant. A total of 18 children were tested with speech audiometry; participant selection criteria were not reported. Results suggested that children reached a higher word discrimination score (WDS %) in quiet with bilateral implants than with monaural implants. WDS for bilateral cochlear implants was 86%, left implant was 75%, and right implant was 72% (p<0.05). There was significant improvement in speech discrimination in noise with bilateral implants compared to unilateral implants. The WDS difference between binaural and monaural conditions in speech discrimination in noise WDS was 18% during the first test session and 14% during second test session (p<0.001). Using linear regressions analysis, the time gap between both implants and the age at first implantation did not affect speech discrimination in noise test results.

A number of studies relevant to the benefits and outcomes of bilateral cochlear implantation in children have been published since 2004. Litovsky and colleagues (2006) reported that 9 of 13 (70%) children with bilateral cochlear implants discriminated source separations of ≤ 20o and 7 of 9 children performed better when using bilateral (vs. unilateral) devices. Sharma and colleagues (2005) reported on auditory development in 23 children with unilateral or bilateral devices. In 1 child who received a bilateral device with later (after age 7) implantation of the second ear, the auditory responses in the second device were similar to that seen in "late-implanted" children. Sharma and Dorman (2006) subsequently studied congenitally deaf children to establish the existence and time limits of a sensitive period for the development of central auditory pathways in humans. The investigators reported that central auditory pathways are "maximally plastic" for a period of about 3½ years in children with cochlear implants. Stimulation delivered within this timeframe results in auditory evoked potentials that reach normal values in 3 to 6 months. However, when stimulation occurs after 7 years, changes occur within 1 month, but then have little to no subsequent change.

Peters and colleagues (2007) presented significant study results of bilateral cochlear implantation in children at an annual meeting of the American Otological Society. A total of 30 children, ages 3 years to 13 years, were bilaterally implanted with sequential surgeries at least 6 months apart. All children received their first cochlear implant prior to 5 years of age and "possessed the necessary speech and cognitive skills to complete the speech tests." Other requirements for enrollment were based on speech measures obtained while the children were using the single implant. These included the Multi-syllabic Lexical Neighborhood Test (MLNT in children < 5 years) or the Lexical Neighborhood Test (LNT in children > 5 years) score > 30% at 70 decibels in the first implanted ear, severe to profound hearing loss in the second ear, participation in a rehabilitation program, and normal cochlear anatomy determined by radiographic measures. Children acquired speech perception in the second ear within 6 months. However, children under 8 years of age acquired speech perception in the second ear more rapidly and ultimately gained a higher level of speech understanding than older children. These findings were believed to support the premise of a more "plastic" auditory system at a younger age. Speech perception testing in quiet and noise was performed preoperatively and again post activation at 3, 6, and 12 months in both the unilateral and bilateral conditions. Some older children were also tested at 24 months. The authors reported that sequentially implanted children in all age groups showed better mean speech perception scores in background noise with bilateral implants than with a single implant. Speech performance in quiet was improved to a lesser degree, but this difference did not meet a level of statistical significance. In younger children, speech perception scores improved for 12 months following the second implant while scores for older children plateaued at 6 months. The rate of improvement in speech perception scores in the second ear was inversely related to the child's age at the time of the second implant.

Other studies have reported benefits for children (and adults) with a unilateral cochlear implant with hearing aid in the opposite ear. Ching and colleagues (2006) reported on 29 children (and 21 adults) with unilateral cochlear implants and a contralateral hearing aid. The authors noted that both children and adults derived binaural advantages related to sentence perception in noise and localized sound that was better with bilateral cochlear implants. In another report, Holt and colleagues (2005) concluded that children with severe hearing loss who used a unilateral cochlear implant benefited from wearing an appropriately-fitted hearing aid in the nonimplanted ear to maximally benefit from bilateral stimulation.

Cochlear Implantation in Infants Younger than 12 Months of Age

Other studies and developments in clinical practice have occurred with the advent of universal neonatal hearing screening in some countries and the availability of screening programs for at-risk infants in other countries, including earlier referral, diagnosis, and intervention for infants with hearing loss. Improvements in device technology, over 2 decades of pediatric clinical experience, and a growing recognition of the efficacy of cochlear implants have led to increasing numbers of young children receiving cochlear implants. There are multiple small retrospective studies and small and large case series which suggest improved health outcomes in several objective measures in children implanted before 12 months of age. There is some data to suggest that earlier implantation leads to improved language acquisition during this critical period of development of spoken and aural language skills; it has been shown that the age at the time of auditory stimulation is a strong predictor of auditory and language outcomes (Harrison, 2005; Miyamoto, 2005; Nicholas, 2006; Sharma, 2005; Tomblin, 2005). Cumulatively, these reports and an increase in recent evidence suggest that cochlear implantation can be performed safely and successfully without serious complications in select children younger than 12 months of age with profound bilateral sensorineural deafness (Colletti, 2005b; Colletti, 2009; Dettman, 2007; Holman, 2013; Holt and Svirsky, 2008; Loundon, 2010; Roland, 2009; Tait, 2007; Valencia, 2008; Vlastarakos, 2010b; Waltzman and Roland, 2005).

In addition to information about children with congenital deafness, there are several small prospective and retrospective case reviews and a matched-pair analysis suggesting that children with profound bilateral sensorineural deafness secondary to bacterial meningitis may benefit from early cochlear implantation (El-Kashlan, 2003; Hehar, 2002; Johnson, 1995; Young, 2000). Philippon and colleagues (2010) performed a descriptive analysis of data, including the cause of meningitis, preoperative imaging evaluation, age at implantation, time lapse between meningitis and implantation, and relevant surgical findings, in an attempt to propose guidelines for the management of profound bilateral sensorineural hearing loss after bacterial meningitis. The mean age at implantation was 3 years 8 months; the mean time delay between meningitis and surgery was 2 years 1 month for the children. A total of 18 children (67%) were implanted within a year. Labyrinthitis ossificans was evidenced at the time of surgery in 62% of the total study subjects (children and adults). Open-set speech discrimination was achieved by 37% of the children (10 of 27). The authors recommended early cochlear implantation for individuals with bilateral profound deafness secondary to bacterial meningitis as an interventionist approach to avoid complications presented by labyrinthitis ossificans and to optimize hearing outcomes.

Peters and colleagues (2010) recently reported on worldwide trends with bilateral cochlear implantation from data collected using a 59 question online electronic survey of 25 clinics (considered as centers of excellence) representing experience with cochlear implantation in over 23,000 users. Cumulatively to the end of 2007, 70% of all bilateral cochlear implant surgeries occurred in children, representing 26% under 3 years of age. Children < 3 years of age also represented the only age group of all individuals in which simultaneous surgeries predominate (58%).

Vlastarakos and colleagues (2010a) conducted a meta-analysis of prospective controlled studies, prospective and retrospective cohort studies, clinical guidelines, and review articles reporting the diagnostic challenges and safety considerations in cochlear implantation in 125 children younger than 12 months of age. Overall, no major anesthetic complication was reported; the rate of surgical complications was reported at 8.8% (3.2% major complications), similar to the respective complication rates in older implanted children (major complications ranging from 2.3 to 4.1%). The authors summarized that cochlear implantation can be performed in otherwise healthy infants, provided that the attending pediatric anesthesiologist is considerably experienced and appropriate facilities of pediatric perioperative care are readily available. A number of concerns, with regard to anatomic constraints, existing co-morbidities or additional disorders, tuning difficulties, and special phases of the developing child should be also taken into account. The meta-analysis did not find an increased rate of anesthetic or surgical complications in implanted infants, although it identified a lack of studies with long-term follow-up reporting improved health outcomes.

Colletti and colleagues (2011) reported on the 10-year results of 19 children who received cochlear implants between the ages of 2 to 11 months, comparing them to 21 children implanted between 12-23 months and 33 children implanted between 24-35 months. Within the first 6 months post-implantation, there was no significant difference among groups in Category of Auditory Performance testing but differences became significantly better in the infant group (early implantation) at the 12- and 36-month testing.

In summary, given the strong evidence of benefit in children with profound hearing loss when cochlear implantation is performed after the age of 12 months, the additional evidence suggesting further benefit at ages < 12 months, and the lack of evidence that performing implantation at an earlier age is harmful, it is reasonable to perform cochlear implantation in children under 12 months of age.

Cochlear Implantation in Special Populations or Clinical Conditions

Several systematic reviews have evaluated outcomes after cochlear implantation for specific causes of deafness and in subgroups of the pediatric population. Eze and colleagues (2013) published a systematic review comparing outcomes of cochlear implantation for children with developmental disability with those without developmental disability. The authors stated that while approximately 30% to 40% of children who receive cochlear implants have developmental disability; evidence about outcomes in this group is limited. A total of 13 studies met the inclusion criteria that compared receptive or expressive language outcomes in children with cochlear implants with and without developmental disability. A meta-analysis of pooled data was not performed as the studies were heterogeneous in terms of comparator groups and outcome measures. Seven of the eligible studies in the structured systematic review demonstrated a significantly poor cochlear implant outcome in children with developmental disability, while the remaining 6 studies reported no significant difference in outcomes between the groups.

Humphriss and colleagues (2013) published a systematic review evaluating outcomes after cochlear implantation in a pediatric population with auditory neuropathy spectrum disorder (ANSD), a sensorineural hearing disorder characterized by abnormal auditory brainstem response with preserved cochlear hair cell function as measured by otoacoustic emissions testing. A total of 27 observational studies were selected for review, including case studies, cohort studies, and comparison studies between children with ANSD and severe sensorineural hearing loss. Eleven of the 15 noncomparative studies did not include a measure of speech recognition before cochlear implantation. Among the comparative studies, those comparing cochlear implantation to "usual care," typically a hearing aid, provided the most information about effectiveness of cochlear implantation among children with ANSD; a single small study that used this design found no significant differences between the groups. The quality of the available evidence was limited by methodological concerns, including risk of bias and confounding.

Fernandes and colleagues (2015) evaluated 18 published studies and 2 dissertations that reported hearing performance outcomes for children with ANSD and cochlear implants. Five studies were nonrandomized controlled trials considered high quality, 5 randomized controlled trials considered low quality, and 10 were clinical outcome studies. A total of 14 studies compared speech perception in children with ANSD and cochlear implants with speech perception in children with sensorineural hearing loss and cochlear implants. Most of the studies (n=13) concluded that children with ANSD and cochlear implants developed hearing skills similar to children with sensorineural hearing loss and cochlear implants; however, these types of studies do not allow comparisons of outcomes between children with ANSD treated with cochlear implants and those treated with usual care.

In a subsequent small retrospective case series, Kontorinis and colleagues (2014) retrospectively evaluated pre- and post-cochlear implantation hearing outcomes for 27 implanted children with ANSD. Cognitive disorders were found in 4 subjects: 3 children were diagnosed with autism and another child with dyspraxia. Another child had severe additional co-morbidities (hemiplegia). One of the autistic children became a non-user of her cochlear implant. The average age at implantation was 35.4 months (range, 19-68 months) with follow-up for an average of 63.1 months (range, 6-140 months). Nine children were implanted bilaterally and 18 unilaterally. The mean preoperative categories of auditory performance (CAP) and Manchester spoken language development scale (MSLDS) scores with hearing aids were 2.5 (range, 0-5) and 2.5 (range, 0-6), respectively. The mean post-cochlear implant CAP and MSLDS scores were 5.8 (range, 2-9) and 7.7 (range 3-10), respectively. The difference between the preoperative and post-cochlear implant scores was statistically significant for both CAP (p<0.001) and MSLDS (p<0.001). In 3 children the post-cochlear implant outcomes were fluctuating. The authors identified cognitive disorders as a significantly negative prognostic factor for cochlear implant outcome. Limitations of this study include the retrospective design and lack of information on how many children would have otherwise qualified for a cochlear implant without ANSD.

In summary, additional well designed studies are needed to draw any conclusions around the effectiveness of cochlear implantation in improving speech recognition in children with ANSD.

Hybrid Cochlear Implantation 

On March 20, 2014, the FDA granted premarket approval (PMA) status to the Nucleus Hybrid™ L24 Cochlear Implant System (Cochlear Americas, Englewood, CO), a unilateral cochlear implant intended to provide electric stimulation to the mid-to-high frequency region of the cochlea and acoustic amplification to the low frequency regions. The implant is proposed for use by individuals with residual low frequency hearing sensitivity who have obtained limited benefit from bilateral conventional hearing aids. The Hybrid L24 is an electric-acoustic stimulation (EAS) cochlear implant system that consists of both internal and external components. The FDA approval of the Hybrid L24 was based on a multicenter, nonrandomized, unblinded single-subject study where participants served as their own control (so that post-implant performance was compared to each participant's baseline or pre-implant performance) (Roland, 2016). According to the FDA PMA (P130016), criteria for study inclusion required that candidates be aged 18 years and older with preoperative hearing ranges from normal to moderate hearing loss in the low frequencies (thresholds no poorer than 60 decibels HL up to and including 500 hertz), with severe to profound mid-to-high frequency hearing loss (threshold average of 2000, 3000, and 4000 hertz ≥ 75 decibels HL) in the ear to be implanted, and moderately severe-to-profound mid-to-high frequency hearing loss (threshold average of 2000, 3000, and 4000 hertz ≥ 60 decibels HL) in the contralateral ear. A CNC word recognition test score was required to be between 10% and 60%, inclusively, in the ear to be implanted in the preoperative aided condition and in the contralateral ear, equal to or better than that of the ear to be implanted, but not more than 80% correct. Individuals with severe to profound high-frequency hearing loss for > 30 year's duration or congenital hearing loss (onset prior to 2 years of age) were excluded from participation. Prospective candidates were required to go through a suitable 2 week hearing aid trial unless already appropriately fitted with conventional hearing aids.

The study was conducted at 10 United States sites, enrolled 50 participants (age at implantation, range: 23 to 86.2 years), and involved up to 9 visits before and after implantation for approximately a 1-year period. The Hybrid L24 was implanted in one ear and activated following a healing period of 2 to 4 weeks. Postoperative measurements included verification of hearing device functioning, unaided hearing thresholds and tympanometry, aided audiometric thresholds, aided CNC test in quiet, aided AzBio sentences-in-noise test, and adverse event reporting at 3-, 6-, and 12-month intervals. Co-primary effectiveness endpoints included CNC word-recognition scores and AzBio sentence-in-noise scores compared across 2 conditions: the baseline "Acoustic Alone" condition and the 6-month "postactivation Hybrid" condition. Success was defined as statistically significant improvement in both co-primary endpoint measures. A total of 49 of the 50 enrolled participants (98%) completed all effectiveness outcome assessments at the 6-month interval, while 48 participants completed the audiometric testing for hearing sensitivity; 46 subjects were evaluable at the 12-month interval. Based on data from 50 participants (including worst-case imputed scores for data missing for 1 participant), both co-primary effectiveness endpoints were met. Statistically significant improvements in mean CNC word score (35.7%: 27.8% to 43.6%; 95% CI, p<0.0001) and mean AzBio sentence-in-noise score (32.0%: 23.6% to 40.4%; 95% CI, p<0.0001) occurred from the baseline (Acoustic alone, hearing-aided) to the 6-month interval postactivation (Hybrid condition), respectively. Secondary effectiveness endpoints compared 6-month postoperative performance in the Hybrid condition to preoperative (ipsilateral) Acoustic Alone performance. All secondary endpoints were met as more than 75% of the participants performed similar to or better on each of the 3 specified measures: CNC words (96%), CNC phonemes (96%), and AzBio sentences (88%).

The primary safety endpoint was the number and proportion of participants experiencing an adverse event, defined as any surgical and/or device events. A total of 71 adverse events were reported to have occurred during the study. Of the 50 implanted participants, 34 (68%) experienced at least 1 adverse event, with multiple (2 to 4) adverse events experienced by 20 to 50 subjects; 24 of 71 adverse events in 23 participants were unresolved during the study. The two most frequently observed adverse events that were reported as resolved included tinnitus-related issues and device-related open shorts experienced by 28% and 22% of participants, respectively. By May 31, 2013, 30 of 50 (60%) participants exhibited more than a 30 decibels loss in their residual low-frequency hearing. Unresolved adverse events observed included profound/total loss of residual low-frequency hearing occurring in 22 of 50 (44%) participants. As of February 10, 2014, 6 of 50 (12%) participants were subsequently explanted and reimplanted with a standard cochlear implant. Based on these results, the FDA stated "It is yet to be determined over the long-term how many additional subjects who experience profound loss will be explanted and re-implanted with a traditional cochlear implant array."

Despite an improvement in speech recognition in terms of CNC words and AzBio sentences reported for the majority of the study population, the FDA concluded the potential risks of profound and possibly total loss of low-frequency hearing that occurred in 44% of the participants:

 …is a known risk and renders the device usage to electrical (cochlear implant) stimulation only since the acoustic amplification is ineffective for these levels of hearing loss. For subjects who lost low-frequency residual hearing to the profound/total level(s), the device showed benefit for only about half (9 of 17) or 53% of these subjects. Furthermore, 6/50 subjects who lost residual low-frequency hearing chose to undergo explantation of the Hybrid L24 and be reimplanted with an approved standard cochlear implant.

Considering the risks and benefits of the device, the FDA approved the hybrid implant only for unilateral use after a sufficient trial of conventional hearing aids, with an expiration date at 1 year. Continued approval of the PMA is contingent upon the submission of periodic reports, which includes reporting of device distribution in order to determine the frequency and prevalence of adverse events.

In 2016, Roland and colleagues published the results of the multicenter clinical trial presented to the FDA (2014) as part of the Nucleus Hybrid L24 implant system PMA review process. The study inclusion criteria (discussed previously in this document), evaluated 50 individuals aged 18 years or older with low-frequency hearing and severe-to-profound high-frequency sensorineural hearing loss who were implanted with the hybrid device at 10 clinical sites in the United States. Acoustic thresholds were measured for each ear preoperatively and postoperatively, at device activation, and 3, 6, and 12 months post-activation. The outcomes reported were consistent with the clinical trial data submitted to the FDA, that is, participants experienced a significant mean improvement (p<0.001) in both co-primary endpoints with the hybrid device over a preoperative hearing aid: CNC words (35.8 ± 27.9 percentage point change; 95% CI 27.9, 43.7) and AzBio sentences in noise (32.0 ± 29.4 percentage point change; 95% CI, 23.7, 40.4); secondary endpoints were met with the hybrid implant relative to performance with a hearing aid. Of the 17 participants that did not maintain functional acoustic hearing, 5 participants chose to have the hybrid implant explanted and replaced with a standard cochlear implant. A total of 65 adverse events were reported involving 34 of 50 participants. The most frequently occurring adverse events were profound/total hearing loss (22 events [33.8%] in 22 participants [40%]), open/short-circuited electrodes (11 events [16.9%] in 11 participants [22%]), and increased tinnitus or tinnitus not present preoperatively (6 events each [9.2%] in 6 participants [12%]). A total of 50 adverse events including tinnitus, vertigo, and other symptoms, were considered to be medical or surgically associated with a mastoidectomy with the facial recess approach used in cochlear implantation. Limitations of this clinical trial as identified by the authors include the nonrandomized design, small number of participants, and short duration of follow-up.

The results of an industry-sponsored prospective study conducted at 16 European cochlear implant centers evaluated the performance benefits up to 1 year post-Hybrid L24 implantation in terms of speech recognition, sound quality, and quality of life (Lenarz, 2013). Postoperative performance using a Freedom Hybrid sound processor was compared with that of preoperative hearing aids in 66 individuals with bilateral severe-to-profound high-frequency hearing loss. The group median increase in air conduction thresholds in the implanted ear for test frequencies 125 to1000 hertz was < 15 decibels across the population, both immediately and 1 year postoperatively. A total of 88% of subjects used the Hybrid L24 processor at 1 year post-implantation. A total of 65% of subjects had significant gain in speech recognition in quiet, and 73% in noise (≥ 20 percentage points per 2 decibel signal-to-noise ratio). The mean Speech Spatial Qualities (SSQ) of Hearing Questionnaire subscale scores were significantly improved (+1.2, +1.3, +1.8 points, p<0.001), as was the mean health utility-13 (HUI3) score (+0.117, p<0.01). Combining residual hearing with the hybrid device implantation gave 22 to 26 percentage points mean benefit in speech recognition scores over hybrid device implantation alone (p<0.01). Partially preserved residual hearing was maintained in 89% of subjects within 1 month follow-up, however, some degradation was reported over time with 74% of subjects retaining residual hearing within 30 decibels or preoperative levels at 1 year, and approximately 50% retained hearing within 15 decibels. There were 16 subjects whose 500 hertz thresholds increased by > 30 decibels, with 4 of 16 participants obtaining a large gain in speech recognition score for the implanted ear (55 to 65 percentage points), although the remainder of subjects had limited benefit as either no change (8 of 16 participants) or a reduced score was reported. One subject withdrew from the study after 1 month follow-up due to non-device related health problems and 4 subjects withdrew after 6 months follow-up. The authors reported missing data and inconsistent data collection throughout the study, in particular, at the 1-year primary endpoint for a total of 5 subjects, so only 6-month speech recognition scores were used if available for the Hybrid L24 implanted ear and best aided pre-to postoperative comparisons. Three adverse events were reported during the study which may have been related to the device or surgery, including prickling pain below the eye/sinusitis, middle-ear infection, and dizziness. Two individuals required re-positioning of the implant device due to poor fixation, and confirmed partial extrusion of the electrode array.

Gantz and colleagues (2016) reported on the final outcomes of a multicenter, longitudinal, single-subject (three- stage) study conducted between 2002 and 2011 evaluating 87 individuals implanted with a Nucleus Hybrid S8 implant for high-frequency hearing loss. Speech perception in quiet (CNC words) and in noise (Bamford-Kowal-Bench Sentences-In-Noise [BKB-SIN]) were collected pre- and postoperatively at 3, 6, and 12 months. Subjective questionnaire data were also collected using the Abbreviated Profile for Hearing Aid Benefit (APHAB). The surgical implantation of the 10-mm electrode in the scala tympani resulted in some level of hearing preservation in 98% of participants, with 90% maintaining a functional low-frequency pure tone average (PTA) at initial activation. Two participants experienced immediate postoperative total hearing loss. An additional 6 participants lost enough hearing in the low frequencies to be considered nonfunctional. At 3 months post-activation, a total of 14 participants experienced a total loss of hearing in the implanted ear and nonfunctional hearing. An additional 2 participants experienced total hearing loss at 12 months post-activation, resulting in 16 (18%) participants with nonfunctional hearing loss at 12 months. Data was available for 75 participants at the 12-month evaluation. A significant percentage of participants demonstrated improvement in speech perception as measured by CNC words: 82.5% of participants in the hybrid ear (that is, combined acoustic and electric in the same ear) and 87.5% of participants in the hybrid and combined condition (that is, acoustic plus electric combination when listening with both ears plus the Hybrid S8 device). In addition, all participants reported positive improvements in hearing in three of the four subscales of the APHAB. A total of 14 participants requested explantation of the Hybrid S8 implant for various reasons of dissatisfaction with the device and subsequently had placement of a standard length Nucleus Freedom cochlear implant. The authors concluded that combining acoustic plus electric speech processing has significant advantages for hearing-impaired individuals with residual low-frequency hearing. Limitations of this study include a lack of data to confirm the etiology of the decline in acoustic hearing sensitivity that resulted in the 19% rate of individuals with nonfunctional hearing loss at 12 months.

In summary, for individuals who have high-frequency sensorineural hearing loss with preserved low-frequency hearing who receive a hybrid cochlear implant, there are inherent risks of surgical implantation, frequency of adverse events post-implantation, and the potential for profound and possibly total loss of low-frequency hearing resulting in explantation of the device and reimplantation with an FDA-approved standard cochlear implant. The available evidence reporting relevant outcomes includes prospective and retrospective studies using single-arm, within-subject comparison pre- and post-intervention (Gantz, 2016; Lenarz, 2013; Roland, 2016). These trials, along with the views of relevant medical specialists practicing in otolaryngology and neurotology suggest that for individuals with high-frequency sensorineural hearing loss with preserved low-frequency hearing, hybrid cochlear implantation is associated with improvements in hearing of speech in quiet and noise. In addition, the available evidence also suggests that a hybrid cochlear implant improves speech recognition better than a conventional hearing aid alone in select individuals.  

Auditory Brainstem Implants (ABI)

The FDA approval of the Nucleus® 24 Auditory Brain Stem Implant System (Cochlear Americas, Englewood, CO) was based on results of a case series of 90 individuals (Donaldson, 2001). Of the 90 individuals evaluated, 28 complications occurred in 26 individuals; 26 of these complications resolved without surgical or extensive medical intervention. Two individuals had infections of the postoperative flap requiring explantation of the device. Effectiveness outcomes were evaluated in 60 individuals with a minimum experience of 3 to 6 months with the device. Device benefit was defined as a significant enhancement of lip-reading or an above-chance improvement on sound-alone tests. Based on this definition, a total of 95% (57 of 60) derived benefit from the device. While the use of an ABI is associated with a modest improvement in hearing, this level of improvement is considered significant in this group of individuals with no other treatment options. Among the 90 individuals receiving the implant, 16 did not receive auditory stimulation from the device postoperatively, either due to migration of the implanted electrodes or surgical misplacement. To place the electrode array on the surface of the cochlear nucleus, the surgeon must be able to visualize specific anatomical landmarks. Because large neurofibromas compress the brainstem and distort the underlying anatomy, it may be difficult or impossible for the surgeon to correctly place the electrode array. For this reason, individuals with large, longstanding tumors may not benefit from the device.

Colletti and colleagues (2005a) presented data from ABI in 16 children and adults who had non-tumor diseases of the cochlear nerve or cochlea and 13 individuals with neurofibromatosis type 2 (NF-2). Ages of individuals ranged from 14 months to 70 years, the non-tumor group included individuals with head trauma, complete ossification, 1 child with auditory neuropathy, and 5 children with bilateral cochlear nerve aplasia. Following implantation, the adult non-tumor group scored substantially higher than the NF-2 group in open set speech perception tests, some of the children showed dramatic improvements in word and sentence recognition over a 1 year follow-up. Short-term side effects included dizziness or tingling sensations in the leg, arm, and throat (20 of 29 individuals). The investigators suggested that ABIs hold promise for individuals with cochlear and cochlear nerve abnormalities when cochlear implants are not indicated. Studies from Europe report improvement in hearing with these devices in "non-tumor" individuals. L. Colletti (2007) reported results on 22 non-neurofibromatosis individuals and V. Colletti (2006) reported results on 14 post-surgically removed NF-2 individuals and 25 non-tumor individuals who were fitted with an ABI. In the latter study, the non-tumor individuals had cochlear or cochlear nerve injuries or malfunctions including bilateral labyrinthine fractures, bilateral temporal bone fracture, incomplete cochlear partition (Type II or Mondini malformations) and alterations in cochlear patency (for example, complete bilateral cochlear ossification, cochlear derangement due to meningitis, otosclerosis, and autoimmune diseases). Colletti (2006) reported better outcomes in the non-tumor group compared to NF-2 group when evaluated with a series of "psychophysical" tests. This study is limited in drawing conclusions as to the benefit of an ABI in non-tumor individuals due to the small sample size and heterogeneous composition of the study population. Colletti and colleagues (2013) reported on ABIs in 21 children, ranging in age from 1.7 to 5 years, with deafness unrelated to neurofibromatosis, who had a poor response to cochlear implants. At the time of surgery, the cochlear nerve was found to be absent in each of the children. Significant improvement in Category of Auditory Performance (CAP) scale was reported after ABI (p<0.001); however, sufficient data are lacking to substantiate improvement in long-term hearing outcomes for this indication.

Merkus and colleagues (2014) reported on a systematic review of ABIs for non-NF2 indications which included 144 non-NF2 ABI cases from 31 publications. Non-NF2 indications for which ABIs were evaluated included auditory neuropathy, autoimmune inner ear disease, bilateral traumatic cochlear nerve disruption, cochlear nerve aplasia, cochlear otosclerosis, temporal bone fractures, and vestibular schwannoma (in the only hearing ear). Cochlear implants generally resulted in better hearing than ABIs when the cochlea and cochlear nerve were intact. Complete bilateral disruption of the cochlear nerve from trauma did not exist in the literature and cochlear malformation did not preclude cochlear implantation. While comparative evidence is limited, cochlear implants appeared to demonstrate greater hearing benefits than ABI in individuals with non-NF2 indications. It was suggested that ABI may only have potential for improved outcomes in bilateral complete cochlear and inner ear aplasia, when imaging and electrophysiologic testing demonstrate that the cochlear nerve is absent. At this time, however, the available evidence in the peer-reviewed published literature is limited in drawing conclusions on the benefits of ABI for these individuals.

Sennaroglu and colleagues (2016) reported on the long-term outcomes of 35 of 60 prelingually deaf children in Turkey who received one of three different ABI models implanted for severe inner ear malformations. A total of 19 children in the analysis were deaf due to cochlear hypoplasia. At regular follow-up, children were evaluated with the CAP, Speech Intelligibility Rate (SIR), Functional Auditory Performance of Cochlea Implantation (FAPCI), and Manchester scores. Approximately one-half of the children were in the CAP category 5 and could understand common phrases without lip reading. In the subgroup with better hearing thresholds (25-40 decibels), some children (17.6%) were able to understand conversation without lip reading, use the telephone with known speaker (11.8%), and follow group conversation in a noisy room (5.9%). For children with higher hearing thresholds (> 50 decibels), none exceeded CAP category 5. SIR and Manchester scores were also better with greater hearing thresholds. Auditory performance measured with the FAPCI was in the 10th percentile for all groups and was worse compared to cochlear implantation. Children with additional nonauditory disabilities (for example, intellectual challenges) had worse outcomes. The authors reported that hearing progress was faster in the initial 2 years when compared with longer use of the ABI. Limitations of this study include the small number of participants in each hearing anomaly group which resulted in lack of certain statistical comparisons of outcomes. Additionally, as most children will have device failure at least two or three times over their lifespan, complications of revision surgery may result because of fibrotic changes in the lateral recess of the ear channel.

Puram and colleagues (2016) reported on the safety and efficacy of ABI surgery in an ongoing FDA-regulated investigational device exemption trial (NCT01864291) of children with pre-or postlinguistic deafness not eligible for cochlear implantation. Of 17 candidates who were evaluated, 5 (average age, 19.2 months) met the study selection criteria and underwent ABI implantation with a Nucleus AB124. The age at implantation ranged from 11 months to 2.5 years. All 5 children experienced responses including babbling and responses to sounds and speech after implantation with no major complications (such as, cerebral spinal fluid leak). Two of 4 children had complete device failures: 2 failures in one child secondary to mechanical falls (at 6 and 7 months post-implantation), and one child required revision surgery for device failure at 1 month post-surgery. Due to the small study population, additional study is required that includes a larger cohort of participants combining data from multiple ABI centers in the United States.  

To date, the Nucleus 24 Auditory Brain Stem Implant has received FDA approval only for individuals with NF-2 following tumor removal.

Background/Overview

Single or Multi-Channel Cochlear Implants

A single or multi-channel cochlear implant provides direct electrical stimulation to the auditory nerve, bypassing the usual transducer cells that are absent or nonfunctional in deaf cochlea. The basic components of a cochlear implant include both external and internal components. The external components include a microphone headset, an external sound processor, and an external transmitter/audio input selector. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear. The microphone picks up sounds that are carried to the external sound processor and transformed into coded signals that are then transmitted transcutaneously to the implanted internal receiver. The receiver converts the incoming signals to electrical impulses, which are conveyed to the electrode array, ultimately resulting in stimulation of the auditory nerve.

Once an individual is referred to a cochlear implant center, the implant team will perform additional testing to determine whether or not the individual is a suitable candidate for cochlear implantation. This testing includes audiologic testing, psychological testing, medical examination, and additional tests performed by the surgeon. An otolaryngologist examines the ear canal and middle ear to ensure that no active infection or other abnormality precludes the implant surgery; a physical examination identifies any potential problems with the use of general anesthesia needed for the implant procedure. The process often involves evaluation using radiographic tests such as computerized tomography scan or magnetic resonance imaging to evaluate the inner ear anatomy.

A speech-language pathologist and audiologist are involved in the cochlear implant evaluation process, performing extensive hearing tests that include pure tone and speech audiometric tests to determine how much the individual can hear with or without a hearing aid. An audiologist may perform objective measures of auditory function in infants and the youngest children as an alternative to standard testing methods. These testing methods define hearing loss is rated on a scale based on the threshold of hearing. Severe hearing loss is defined as a bilateral hearing threshold of 70 to 90 decibels, and profound hearing loss is defined as a bilateral hearing threshold of 90 decibels and above. Electrophysiological and objective measures have a valuable role in the management of individuals receiving cochlear implants; and in particular, young children, complex cases, and difficult-to-test persons. A challenge of performing these studies in children < age 1 year is the lack of available, effective tools for measuring speech perception abilities, including concern regarding the reliability of audiometric results for this age group. Behavioral audiometric testing, the standard for measuring hearing sensitivity, is performed in infants using visual reinforcement audiometry but is not appropriate for infants < age 5.5 months because they do not respond to sound with directed head turns (Holt and Svirsky, 2008). Therefore, audiologists use objective measures of auditory function as an alternative, including evoked otoacoustic emissions (OAE) testing, auditory brainstem response testing (ABR), and auditory steady-state response testing (ASSR) to assess various elements of the auditory system. Electrically evoked auditory brainstem responses (EABR), middle latency responses (MLR), or acoustic reflexes (EART) may be used intraoperatively with stimuli delivered to the cochlear implant prior to leaving the operating room or postoperatively on an outpatient basis to facilitate the implant fitting process. These objective measures are also useful in a small subset of children who are unable to respond consistently to the electrical stimuli used to program the speech processor after implantation. The promontory/round window EABR (prom-EABR) stimulation test (or PST) may be indicated in a small subset of infants and children with conditions such as congenital malformations, cochlear nerve dysplasia or selected aplasia, or narrow internal auditory canal, to confirm the integrity of the auditory nerve (Nikolopoulos, 2000). For cochlear implantation performed in centers in the United States, the PST is no longer considered to be a prognostic factor, as the majority of the test results are recorded as "positive;" however, some centers continue to use the PST results during the implant evaluation process as an exclusion for candidates with complete absence of preoperative ability to stimulate the auditory nerve (Kuo, 2002).

One of the most commonly used speech recognition tests performed in the evaluation of adolescent and adult cochlear implant candidates is the HINT, which measures an individual's ability to hear speech in quiet and in noise in the context of sentences. Psychological counseling of candidates is also performed. These tests are completed to ensure that the candidate will benefit from implantation and are motivated to participate in the process. It is important that the candidate understands what the implant will and will not do, and also understands the commitment required for care and follow-up services (NIDCD, 2016).

Several FDA-approved cochlear implant systems are commercially available in the United States.

Cochlear Implant Manufacturer

 

Advanced Bionics® Corporation (Valencia, CA) Cochlear Americas (Englewood, CO) MED-EL Corporation, USA (Durham, NC)
Currently Marketed Cochlear Implant Systems HiResolution® Bionic Ear System (HiRes 90K)

Cochlear Nucleus® System includes Nucleus 5 and 6 series of CI devices

 

Maestro (Sonata or Pulsar)

Synchrony CI (FDA approved for 3.0T MRI without magnet removal)

Predecessor Cochlear Implants Clarion Multi-Strategy or HiFocus CII Bionic Ear (P940022)  Nucleus 22, 24, Freedom with Contour (P840024) Combi 40+ (P000025)

Subsequent generations of the various components of these devices have focused on improved electrode design and speech processing capabilities. Furthermore, smaller devices and the accumulating experience with use of cochlear implants in children have resulted in broadening of the candidate selection criteria to include children as young as 12 months of age. Specific criteria vary with the type of device. The FDA-labeled indications for each device are available on the FDA Premarket Approval (PMA) website (FDA, 2017).

While the benefits of unilateral cochlear implants are well accepted, the implantation of a single device does not provide normal (binaural) hearing to an individual with severe bilateral hearing loss. Binaural hearing provides certain auditory effects that assist in localizing sound and understanding speech in a noise environment. The auditory benefits enabled by binaural hearing include addressing "head shadow," "binaural summation," and "binaural squelch" (Gantz, 2002). Head shadow is the barrier the head creates between sounds emitted from one direction and the contralateral ear. Head shadow dampens noise reaching the contralateral ear and delivers an intelligible signal to noise (SNR) or "speech-to-noise" ratio. Head shadow is believed to permit a bilateral cochlear implant user the flexibility of attenuating to the ear with the better SNR. This shadowing or attenuating effect works best for high frequency sounds.

With binaural hearing, each ear receives both unique and redundant information (acoustical representation) that is processed in the brain. The processing of this redundant information, "binaural summation," improves hearing threshold and increases sensitivity to small differences in sound frequency and intensity. Binaural summation can lead to improved speech perception in both quiet and noise. The third effect of binaural hearing is "binaural squelch." With two ears, the brain uses cues to separate sounds coming from different locations. Optimal sound localization requires the ability to detect differences in time and amplitude between signals reaching both ears (Tyler, 2003).

Hybrid Cochlear Implants

The Nucleus Hybrid L24 Cochlear Implant System (also referred to as "Hybrid L24") is a cochlear implant system used to treat certain hearing losses caused by faulty inner ear function. The Hybrid L24 is designed to allow individuals to hear in two ways: electrically (similar to approved cochlear implants) for severe to profound hearing loss at mid and high frequencies, and acoustically (similar to hearing aids) for normal to moderate hearing loss at low frequencies. The Hybrid L24 includes an implant consisting of a receiver/stimulator and an intracochlear electrode array using short implant electrodes placed in the cochlea through a small cochleostomy or round window insertion to preserve low-frequency hearing. An externally worn sound processor can be fit with an acoustic component, programming software/instruments, and various remote control options. Using a small microphone, the sound processor picks up sound from the person's surroundings and separates it into different groups of sounds by frequency (that is, the low or high "pitch" of a sound). The higher frequency information about the sound is sent to the receiver/stimulator and electrode array of the implanted part of the device. Since the electrode array is located inside the person's cochlea, this sound-related information is relayed to the brain, allowing the person to hear. For person's who have enough of their own acoustic low-frequency hearing after implantation, the sound processor also provides amplified low-frequency sound to the ear through the acoustic component. After implantation, some persons do not have enough low-frequency hearing to use the acoustic component so these individuals hear only electrically using the implant for all (lower and higher) sound frequencies (FDA, 2014).

According to the clinical trial data reported to the FDA in the PMA information (FDA, 2014), the implant is intended for use in one ear by persons aged 18 years or older who obtain limited benefit from appropriately fitted conventional hearing aids in both ears and meet the following criteria:

The Hybrid L24 should not be used for individuals who have any of the following conditions:

Other hybrid hearing devices have been developed but do not have FDA 510(k) clearance or premarket approval for use in the U.S., including the Synchrony Electric Acoustic Stimulation (EAS) Hearing Implant System (MED-EL, USA, Durham, NC). The hybrid implant's manufacturer states it is designed for use in individuals with "partial deafness," that is, mild to moderate low-frequency hearing loss combined with profound hearing loss in the higher frequencies.

Centers for Disease Control and Prevention (CDC) Notifications

Cochlear implant recipients should be up-to-date on age-appropriate pneumococcal conjugate and Haemophilus influenza type b conjugate vaccinations in accordance with current CDC and the Advisory Committee on Immunization Practices (ACIP) recommendations (CDC, 2014).

In 2010, the American Academy of Pediatrics (AAP) issued a policy statement on CI in children addressing surgical site infections and prevention and treatment of acute otitis media and meningitis. The policy statement includes the following recommendations:

Children with profound deafness who are candidates for cochlear implantation should receive all age-appropriate doses of pneumococcal conjugate and Haemophilus influenzae type b conjugate vaccines and appropriate annual immunization against influenza. In addition, starting at 24 months of age, a single dose of 23-valent pneumococcal polysaccharide vaccine should be administered. Before implant surgery, primary care providers and cochlear implant teams should ensure that immunizations are up-to-date, preferably with completion of indicated vaccines at least 2 weeks before implant surgery. Imaging of the temporal bone/inner ear should be performed before cochlear implantation in all children with congenital deafness and all patients with profound hearing impairment and a history of bacterial meningitis to identify those with inner-ear malformations/cerebrospinal fluid fistulas or ossification of the cochlea (Rubin, 2010).

Auditory Brainstem Implants

The ABI is a device designed to restore some hearing in individuals with neurofibromatosis type 2 rendered deaf by bilateral surgical removal of neurofibromas involving the auditory nerve. The device consists of an externally worn speech processor that provides auditory information to an electrical signal that is transferred to a receiver/stimulator implanted in the temporal bone. The receiver stimulator is, in turn, attached to an electrode array implanted on the surface of the cochlear nerve in the brainstem, thus bypassing the inner ear and auditory nerve. The electrode stimulates multiple sites on the cochlear nucleus, which is then processed normally by the brain. One device has received FDA approval for auditory brainstem implantation, the Nucleus 24 Auditory Brain Stem Implant System. The speech processor and receiver are similar to the devices used in cochlear implants; the electrode array placed on the brainstem is the novel component of the device.

Definitions

Auditory brainstem response (ABR): A neurologic test of auditory brainstem function in response to auditory (click) stimuli; the most common application of auditory evoked responses.

Auditory evoked potential: Evaluates the nerve pathways from the ear to the brain; consists of a very small electrical voltage originating from the brain recorded from the scalp in response to an auditory stimulus (for example, different tones, speech sounds).

AzBio Sentences-in-Noise Test: A test to assess a cochlear implant recipient's ability to understand sentences in the presence of background noise.

Cochlea: Part of the inner ear that processes sound.

Consonant-Nucleus-Consonant Test (CNC): An open set word recognition test (administered in quiet) consisting of 10 recorded lists of 50 monosyllabic words used to determine speech intelligibility in listeners with hearing impairments.

Decibel (dB): Unit that measures the intensity or loudness of sound.

Electrically evoked auditory brainstem response (EABR): A measurement of auditory brainstem (ABR) integrity using an electrical stimulus with the purpose of determining if the auditory nerve responds as expected to electrical stimulation. The EABR test may be used presurgically in selected individuals to determine if cochlear implantation should be attempted and postsurgically to determine if the implant is working properly.

Evoked otoacoustic emissions (OAE): Sounds measured in the external ear canal that are a reflection of the working of the cochlea. OAE is used in the screening as well as the diagnosis of hearing impairments in neonates and young children. While the test is considered part of the standard battery of tests in infants, it is considered a specialized test in children and adults.

Meningitis: Inflammation of the meninges, the membranes that surround the brain and the spinal cord; may result in hearing loss or deafness.

Neural plasticity: Ability of the brain, certain parts of the nervous system, or both to adapt to new conditions, such as an injury.

Neurofibromatosis Type 2 (NF-2): Group of inherited disorders in which noncancerous tumors grow on several nerves that usually include the nerve involved with hearing.

Otitis media: Inflammation of the middle ear caused by infection.

Postlingual deafness: Hearing loss that occurs after acquiring language or speech.

Prelingual deafness: Hearing loss that occurs before the development of language or speech.

Promontory/round window stimulation test (PST): The application of controlled electrical current to the promontory or round window niche of the middle ear. The current is delivered via an electrode that is inserted either through the tympanic membrane by myringotomy or puncture by the otolaryngologist. The test has been used to predict the electrical response of surviving spiral ganglion nerve fibers and felt to verify a functioning cochlear nerve.

Scala tympani: The lower tube of the cochlear canal extending from the opening in the medial wall of the middle ear leading into the cochlea.

Sensorineural hearing loss: Hearing loss caused by damage to the sensory cells and/or nerve fibers of the inner ear.

Severity of hearing loss: Severity of hearing loss is defined in terms of decibels (dB); graded as Mild (26-40 dB), Moderate (41-55 dB), Moderately Severe (56-70 dB), Severe (71-90 dB), Profound (90 dB).

Speech recognition test: A test frequently used to determine cochlear implant candidacy; currently used tests include the following:

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Cochlear Implants
When services may be Medically Necessary when criteria are met:

CPT  
69930 Cochlear device implantation, with or without mastoidectomy
69949 Unlisted procedure, inner ear [when specified as implantation of hybrid cochlear device]
   
HCPCS  
L8614 Cochlear device, includes all internal and external components
L8699 Prosthetic implant, not otherwise specified [when specified as hybrid cochlear device, including all internal and external components]
   
ICD-10 Procedure  
09HD05Z-09HD45Z Insertion of single channel cochlear prosthesis into right inner ear [by approach; includes codes 09HD05Z, 09HD35Z, 09HD45Z]
09HD06Z-09HD46Z Insertion of multiple channel cochlear prosthesis into right inner ear [by approach; includes codes 09HD06Z, 09HD36Z, 09HD46Z]
09HE05Z-09HE45Z Insertion of single channel cochlear prosthesis into left inner ear [by approach; includes codes 09HE05Z, 09HE35Z, 09HE45Z]
09HE06Z-09HE46Z Insertion of multiple channel cochlear prosthesis into left inner ear [by approach; includes codes 09HE06Z, 09HE36Z, 09HE46Z]
   
ICD-10 Diagnosis  
H90.3 Sensorineural hearing loss, bilateral
H90.5 Unspecified sensorineural hearing loss
H90.6 Mixed conductive and sensorineural hearing loss, bilateral
H90.8 Mixed conductive and sensorineural hearing loss, unspecified
H91.93 Unspecified hearing loss, bilateral

When services are Investigational and Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met, for all other diagnoses not listed; or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

When services may also be Medically Necessary when criteria are met:

HCPCS  
L8619 Cochlear implant external speech processor and controller, integrated system, replacement
L8627 Cochlear implant, external speech processor, component, replacement
L8628 Cochlear implant, external controller component, replacement
   
ICD-10 Diagnosis  
  All diagnoses

When services are Not Medically Necessary:
For the replacement codes listed above, when criteria are not met; or when the code describes a procedure indicated in the Position Statement section as not medically necessary.

Auditory Brainstem Implants
When services may be Medically Necessary when criteria are met:

HCPCS  
S2235 Implantation of auditory brain stem implant
   
ICD-10 Diagnosis  
D33.3 Benign neoplasm of cranial nerves [when specified as neurofibromatosis type 2]
Q85.00 Neurofibromatosis, unspecified
Q85.02 Neurofibromatosis, type 2

When services are Investigational and Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met or for all other diagnoses, or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

When services may also be Medically Necessary when criteria are met:

HCPCS  
L8699 Prosthetic implant, not otherwise specified [when describing replacement components of an auditory brain stem implant]
   
ICD-10 Diagnosis  
D33.3 Benign neoplasm of cranial nerves [when specified as neurofibromatosis type 2]
Q85.00 Neurofibromatosis, unspecified
Q85.02 Neurofibromatosis, type 2

When services are Not Medically Necessary:
For replacement components, when criteria are not met; or when the code describes a procedure indicated in the Position Statement section as not medically necessary.

References

Peer Reviewed Publications:

  1. Arts RA, George EL, Stokroos RJ, et al. Review: cochlear implants as a treatment of tinnitus in single-sided deafness. Curr Opin Otolaryngol Head Neck Surg. 2012; 20(5):398-403.
  2. Biernath KR, Reefhuis J, Whitney CG, et al. Bacterial meningitis among children with cochlear implants beyond 24 months after implantation. Pediatrics. 2006; 117(2):284-289.
  3. Blasco MA, Redleaf MI. Cochlear implantation in unilateral sudden deafness improves tinnitus and speech comprehension: meta-analysis and systematic review. Otol Neurotol. 2014; 35(8):1426-1432.
  4. Bond M, Elston J, Mealing S, et al. Effectiveness of multi-channel unilateral cochlear implants for profoundly deaf children: a systematic review. Clin Otolaryngol. 2009a; 34(3):199-211.
  5. Bond M, Elston J, Mealing S, et al. Systematic reviews of the effectiveness and cost-effectiveness of multi-channel unilateral cochlear implants for adults. Clin Otolaryngol. 2010; 35(2):87-96.
  6. Bond M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess. 2009b; 13(44):1-330.
  7. Ching TY, Incerti P, Hill M, et al. An overview of binaural advantages for children and adults who use binaural/bimodal hearing devices. Audiol Neurotol. 2006; 11(1 Suppl):6-11.
  8. Colletti L. Beneficial auditory and cognitive effects of auditory brainstem implantation in children. Acta Otolaryngol 2007; 127(9):943-946.
  9. Colletti L. Long-term follow-up of infants (4-11 months) fitted with cochlear implants. Acta Otolaryngol. 2009; 129(4):361-366.
  10. Colletti L, Mandalà M, Zoccante L et al. Infants versus older children fitted with cochlear implants: performance over 10 years. Int J Pediatr Otorhinolaryngol. 2011; 75(4):504-509.
  11. Colletti L, Wilkinson EP, Colletti V. Auditory brainstem implantation after unsuccessful cochlear implantation of children with clinical diagnosis of cochlear nerve deficiency. Ann Otol Rhinol Laryngol. 2013; 122(10):605-612.
  12. Colletti V. Auditory outcomes in tumor vs. non-tumor patients fitted with auditory brainstem implants. Adv Otorhinolaryngol. 2006; 64:167-185.
  13. Colletti V, Carner M, Miorelli V, et al. Auditory brainstem implant (ABI): new frontiers in adults and children. Otolaryngol Head Neck Surg. 2005a; 133(1):126-138.
  14. Colletti V, Carner M, Miorelli V, et al. Cochlear implantation at under 12 months: report on 10 patients. Laryngoscope. 2005b; 115(3):445-449.
  15. Copeland BJ, Pillsbury HC III. Cochlear implantation for the treatment of deafness. Annual Rev Med. 2004; 55:157-167.
  16. Crathorne L, Bond M, Cooper C, et al. A systematic review of the effectiveness and cost-effectiveness of bilateral multichannel cochlear implants in adults with severe-to-profound hearing loss. Clin Otolaryngol. 2012; 37(5):342-354.
  17. Dettman SJ, Pinder D, Briggs RJ, et al. Communication development in children who receive the cochlear implant younger than 12 months: risks versus benefits. Ear Hear. 2007; 28(2 Suppl):11S-18S.
  18. Donaldson GS, Peters MD, Ellis MR, et al. Effects of the Clarion Electrode Positioning System on auditory thresholds and comfortable loudness levels in pediatric patients with cochlear implants. Arch Otolaryngol Head Neck Surg. 2001; 127(8):956-960.
  19. El-Kashlan H, Ashbaugh C, Zwolan T, Telian S. Cochlear implantation in prelingually deaf children with ossified cochleae. Otol Neurotol. 2003; 24(4):596-600.
  20. Eze N, Ofo E, Jiang D, O'Connor AF. Systematic review of cochlear implantation in children with developmental disability. Otol Neurotol. 2013; 34(8):1385-1393.
  21. Fernandes NF, Morettin M, Yamaguti EH, et al. Performance of hearing skills in children with auditory neuropathy spectrum disorder using cochlear implant: a systematic review. Braz J Otorhinolaryngol. 2015; 81(1):85-96.
  22. Gantz BJ, Dunn C, Oleson J, et al. Multicenter clinical trial of the Nucleus Hybrid S8 cochlear implant: final outcomes. Laryngoscope. 2016; 126(4):962-973.
  23. Gantz BJ, Tyler RS, Rubinstein JT, et al. Biaural cochlear implants placed during the same operation. Otol Neurotol. 2002; 23(2):169-180.
  24. Gaylor JM, Raman G, Chung M et al. Cochlear implantation in adults: a systematic review and metaanalysis. JAMA Otolaryngol Head Neck Surg. 2013; 139(3):265-272.
  25. Harrison RV, Gordon KA, Mount RJ. Is there a critical period for cochlear implantation in congenitally deaf children? Analyses of hearing and speech perception performance after implantation. Dev Psychobiol. 2005; 46(3):252-261.
  26. Hehar SS, Nikolopoulos TP, Gibbin KP, O'Donoghue GM. Surgery and functional outcomes in deaf children receiving cochlear implants before age 2 years. Arch Otolaryngol Head Neck Surg. 2002; 128(1):11-14.
  27. Holman MA, Carlson ML, Driscoll CL, et al. Cochlear implantation in children 12 months of age and younger. Otol Neurotol. 2013; 34(2):251-258.
  28. Holt RF, Kirk KL, Eisenberg LS, et al. Spoken word recognition development in children with residual hearing using cochlear implants and hearing aids in opposite ears. Ear Hear. 2005; 26(4 Suppl):82S-91S.
  29. Holt RF, Svirsky MA. An exploratory look at pediatric cochlear implantation: is earliest always best? Ear Hear. 2008; 29(4):492-511.
  30. Humphriss R, Hall A, Maddocks J, et al. Does cochlear implantation improve speech recognition in children with auditory neuropathy spectrum disorder? A systematic review. Int J Audiol. 2013; 52(7):442-454.
  31. Johnson MH, Hasenstab MS, Seicshnaydre MA, Williams GH. CT of postmeningitic deafness: observations and predictive value for cochlear implants in children. Am J Neuroradiol. 1995; 16(1):103-109.
  32. Johr M, Ho A, Wagner CS, Linder T. Ear surgery in infants under one year of age: its risks and implications for cochlear implant surgery. Otol Neurotol. 2008; 29(3):310-313.
  33. Kontorinis G, Lloyd SK, Henderson L, et al. Cochlear implantation in children with auditory neuropathy spectrum disorders. Cochlear Implants Int. 2014; 15(1 Suppl):S51-S54.
  34. Kuhn-Inacker H, Shehata-Dieler W, Muller J, Helms J. Bilateral cochlear implants: a way to optimize auditory perception abilities in deaf children? Int J Pediatr Otorhinolaryngol. 2004; 68(10):1257-1266.
  35. Kuo S, Gibson W. The role of the promontory stimulation test in cochlear implantation. Cochlear Implants Int. 2002; 3(1):19-28.
  36. Lammers MJ, van der Heijden GJ, Pourier VE, Grolman W. Bilateral cochlear implantation in children: a systematic review and best-evidence synthesis. Laryngoscope. 2014; 124(7):1694-1699.
  37. Laszig R, Aschendorff A, Stecker M, et al. Benefits of bilateral electrical stimulation with the nucleus cochlear implant in adults: 6-month postoperative results. Otol Neurotol. 2004; 25(6):958-968.
  38. Lenarz T, James C, Cuda D, et al. European multi-centre study of the Nucleus Hybrid L24 cochlear implant. Int J Audiol. 2013; 52(12):838-848.
  39. Litovsky R, Johnstone, PM, Godar S, et al. Bilateral cochlear implants in children: localization acuity measured with minimum audible angle. Ear Hear. 2006; 27(1):43-59.
  40. Litovsky RY, Parkinson A, Arcaroli J, et al. Bilateral cochlear implants in adults and children. Arch Otolaryngol Head Neck Surg. 2004; 130(5):648-655.
  41. Litovsky RY, Parkinson A, Arcaroli J, et al. Simultaneous bilateral cochlear implantation in adults: a multicenter clinical study. Ear Hear. 2006; 27(6):714-731.
  42. Long CJ, Eddington DK, Colburn HS, et al. Binaural sensitivity as a function of interaural electrode position with a bilateral cochlear implant user. J Acoust Soc An. 2003; 114(3):1565-1574.
  43. Loundon N, Blanchard M, Roger G, et al. Medical and surgical complications in pediatric cochlear implantation. Arch Otolaryngol Head Neck Surg. 2010; 136(1):12-15.
  44. Merkus P, Di Lella F, Di Trapani G et al. Indications and contraindications of auditory brainstem implants: systematic review and illustrative cases. Eur Arch Otorhinolaryngol. 2014; 271(1):3-13.
  45. Morera C, Manrique M, Ramos A, et al. Advantages of binaural hearing provided through bimodal stimulation via a cochlear implant and a conventional hearing aid: a 6-month comparative study. Acta Otolaryngol. 2005; 125(6):596-606.
  46. Muller J, Schon F, Helms J. Speech understanding in quiet and noise in bilateral users of the MED-EL COMBI 40/40+ cochlear implant system. Ear Hear. 2002; 23(3):198-206.
  47. Nicholas JG, Geers A. Effects of early auditory experience on the spoken language of deaf children at 3 years of age. Ear Hear. 2006; 27(3):286-298.
  48. Nikolopoulos TP, Mason SM, Gibbin KP, O'Donoghue GM. The prognostic value of promontory electric auditory brain stem response in pediatric cochlear implantation. Ear Hear. 2000; 21(3):236-241.
  49. Peters BR, Litovsky R, Parkinson A, Lake J. Importance of age and postimplantation experience on speech perception measures in children with sequential bilateral cochlear implants. Otol Neurotol. 2007; 28(5):649-657.
  50. Peters BR, Wyss J, Manrique M. Worldwide trends in bilateral cochlear implantation. Laryngoscope. 2010; 120 (Suppl 2):S17-S44.
  51. Philippon D, Bergeron F, Ferron P, Bussieres R. Cochlear implantation in postmeningitic deafness. Otol Neurotol. 2010; 31(1):83-87.
  52. Puram SV, Barber SR, Kozin ED, et al. Outcomes following pediatric auditory brainstem implant surgery: early experiences in a North American Center. Otolaryngol Head Neck Surg. 2016; 155(1):133-138.
  53. Ramsden R, Greenham P, O'Driscoll M, et al. Evaluation of bilaterally implanted adult subjects with the Nucleus 24 cochlear implant system. Otol Neurotol. 2005; 26(5):988-998.
  54. Reefhuis J, Honein MA, Whitney CH, et al. Risk of bacterial meningitis in children with cochlear implants. NEJM. 2003; 349(5):435-445.
  55. Ricketts TA, Grantham DW, Ashmead DH, et al. Speech recognition for unilateral and bilateral cochlear implant modes in the presence of uncorrelated noise sources. Ear Hear. 2006; 27(6):763-773.
  56. Roland JT Jr, Cosetti M, Wang KH, et al. Cochlear implantation in the very young child: long-term safety and efficacy. Laryngoscope. 2009; 119(11):2205-2210.
  57. Roland JT Jr, Gantz BJ, Waltzman SB, Parkinson AJ; Multicenter Clinical Trial Group. United States multicenter clinical trial of the cochlear nucleus hybrid implant system. Laryngoscope. 2016; 126(1):175-181.
  58. Schoen F, Mueller J, Helms J, Nopp P. Sound localization and sensitivity to interaural cues in bilateral users of the Med-El Combi 40/40+ cochlear implant system. Otol Neurotol. 2005; 26(3):429-437.
  59. Sennaroglu L, Sennaroglu G, Yucel E, et al. Long-term results of ABI in children with severe inner ear malformations. Otol Neurotol. 2016; 37(7):865-872. 
  60. Sharma A, Dorman MF. Central auditory development in children with cochlear implants: clinical implications. Adv Otorhinolaryngol. 2006; 64:66-88.
  61. Sharma A, Dorman MF, Kral A. The influence of a sensitive period on central auditory development in children with unilateral and bilateral cochlear implants. Hear Res. 2005; 203(1-2):134-143.
  62. Sladen DP, Carlson ML, Dowling BP, et al. Early outcomes after cochlear implantation for adults and children with unilateral hearing loss. Laryngoscope. 2016 Oct 12. [Epub ahead of print].
  63. Sladen DP, Frisch CD, Carlson ML, et al. Cochlear implantation for single-sided deafness: a multicenter study. Laryngoscope. 2017; 127(1):223-228.
  64. Tait M, De Raeve L, Nikolopoulos TP. Deaf children with cochlear implants before the age of 1 year: comparison of preverbal communication with normally hearing children. Int J Pediatr Otorhinolaryngol. 2007; 71(10):1605-1611.
  65. Tomblin JB, Barker BA, Spencer LJ, et al. The effect of age at cochlear implant initial stimulation on expressive language growth in infants and toddlers. J Speech Lang Hear Res. 2005; 48(4):853-867.
  66. Tyler R, Dunn CC, Witt SA, Preece JP. Update on bilateral cochlear implantation. Curr Opin Otolaryngol Head Neck Surg. 2003; 11(5):388-393.
  67. Tyler RS, Gantz BJ, Rubinstein JT, et al. Three-month results with bilateral cochlear implants. Ear Hear. 2002; 23(1 Suppl):80S-89S.
  68. Valencia DM, Rimell FL, Friedman BJ, et al. Cochlear implantation in infants less than 12 months of age. Int J Pediatr Otorhinolaryngol. 2008; 72(6):767-773.
  69. van de Heyning P, Vermeire K, Diebl M, et al. Incapacitating unilateral tinnitus in single-sided deafness treated by cochlear implantation. Ann Otol Rhinol Laryngol. 2008; 117(9):645-652.
  70. van Hoesel RJ, Ramsden R, Odriscoll M. Sound-direction identification, interaural time delay discrimination, and speech intelligibility advantages in noise for a bilateral cochlear implant user. Ear Hear. 2002; 23(2):137-149.
  71. van Hoesel RJ, Typer RS. Speech perception, localization, and lateralization with bilateral cochlear implants. J Acoust Soc Am. 2003; 113(3):1617-1630.
  72. Van Schoonhoven J, Sparreboom M, van Zanten BG, et al. The effectiveness of bilateral cochlear implants for severe-to-profound deafness in adults: a systematic review. Otol Neurotol. 2013; 34(2):190-198.
  73. van Zon A, Peters JP, Stegeman I, Smit AL, Grolman W. Cochlear implantation for patients with single-sided deafness or asymmetrical hearing loss: a systematic review of the evidence. Otol Neurotol. 2015; 36(2):209-219.
  74. Verschuur CA, Lutman ME, Ramsden R, et al. Auditory localization abilities in bilateral cochlear implant recipients. Otol Neurotol. 2005; 26(5):965-971.
  75. Vlastarakos PV, Candiloros D, Papacharalampous G, et al. Diagnostic challenges and safety considerations in cochlear implantation under the age of 12 months. Int J Pediatr Otorhinolaryngol. 2010a; 74(2):127-132.
  76. Vlastarakos PV, Proikas K, Papacharalampous G, et al. Cochlear implantation under the first year of age-the outcomes. A critical systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol. 2010b; 74(2):119-126.
  77. Waltzman SB, Roland JT Jr. Cochlear implantation in children younger than 12 months. Pediatrics. 2005; 116(4):e487-e493.
  78. Young NM, Hughes CA, Byrd SE, Darling C. Postmeningitic ossification in pediatric cochlear implantation. Otolaryngol Head Neck Surg. 2000; 122(2):183-188.

Government Agency, Medical Society, and Other Authoritative Publications:

  1. Agency for Healthcare Research and Quality (AHRQ). Effectiveness of cochlear implants in adults with sensorineural hearing loss [Internet]. Technology Assessment Report. 2011 June. Project ID: AUDT0501. Available at: http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id80TA.pdf. Last accessed May 10, 2017.
  2. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Available at: http://www.entnet.org/content/position-statements. Accessed on May 10, 2017.
    • Cochlear implants. Reaffirmed March 2, 2014.
    • Minimal test battery for cochlear implants. Reaffirmed September 17, 2016.
  3. Centers for Disease Control and Prevention (CDC). Immunization Schedules. Available at: http://www.cdc.gov/vaccines/schedules/index.html. Accessed on May 10, 2017.
  4. Centers for Disease Control and Prevention (CDC). Vaccines and preventable diseases: cochlear implants & meningitis vaccination. April 8, 2014. Available at: http://www.cdc.gov/Vaccines/vpd-vac/mening/cochlear/dis-cochlear-faq-hcp.htm. Accessed on May 10, 2017.
  5. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination: Cochlear Implantation. NCD #50.3. Effective April 4, 2005. Available at: http://www.cms.hhs.gov/mcd/index_list.asp?list_type=ncd. Accessed on May 10, 2017.
  6. Rubin LG, Papsin B. Committee on Infectious Diseases and Section on Otolaryngology-Head and Neck Surgery. Cochlear implants in children: surgical site infections and prevention and treatment of acute otitis media and meningitis. Pediatrics. 2010; 126(2):381-391.
  7. U.S. Food and Drug Administration (FDA). Medical Devices Databases. Cochlear implants. Rockville, MD: FDA. Available at: http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm. Accessed on May 10, 2017.
  8. U.S. Food and Drug Administration (FDA). Post-Approval Studies. P130016. Nucleus Hybrid L24 Cochlear Implant System. Last updated April 24, 2017. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?c_id=2396&t_id=513624. Accessed on May 10, 2017.
  9. U.S. Food and Drug Administration (FDA). Premarket Approval Database. Summary of Safety and Effectiveness. Rockville, MD: FDA. Nucleus Hybrid L24 Cochlear Implant System. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm . Accessed on May 10, 2017.
Websites for Additional Information
  1. American Speech-Language-Hearing Association (ASLHA). Cochlear implants. Available at: http://www.asha.org/public/hearing/treatment/cochlear_implant.htm. Assessed on May 10, 2017.
  2. National Institute on Deafness and other Communication Disorders (NIDCD). Hearing, ear infections, and deafness. Available at: http://www.nidcd.nih.gov/health/hearing/Pages/Default.aspx. Accessed on May 10, 2017.
    • Cochlear implants. Updated March 6, 2017.
    • Vestibular schwannoma (acoustic neuroma) and neurofibromatosis. Updated March 6, 2017.
Document History

Status

Date

Action

Revised 08/03/2017 Medical Policy & Technology Assessment (MPTAC) review. Removed abbreviations from the Position Statement section. Added a *Note to the MN criteria that for a young child, a parent or guardian may act as the surrogate for participation in a post-cochlear implant rehabilitation program in order to achieve benefit from the cochlear implant device. Other format changes throughout document. Updated Rationale, References, and Websites for Additional Information sections.
Revised 08/04/2016 MPTAC review. Updated formatting in Position Statement section. Added cochlear implantation with an FDA-approved hybrid cochlear implant device as MN for an individual 18 years of age and older with bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity (that is, able to hear low-frequency sounds) when criteria are met. Removed hybrid cochlear implants from INV&NMN statement. Updated Rationale, Background, References, and Websites for Additional Information sections. Updated Coding section and removed ICD-9 codes.
Revised 08/06/2015 MPTAC review. Clarified medically necessary statement for cochlear implants, adding "pure tone average (PTA)" to the hearing threshold measurement. Added a medically necessary statement for subsequent bilateral cochlear implantation (that is, sequential implantation) of an FDA approved cochlear implant without retesting of hearing when criteria are met at the time of the initial (first) cochlear implantation. Added examples of conditions when cochlear implantation is considered investigational and not medically necessary. Updated Rationale, Background, References, and Websites for Additional Information sections.
Reviewed 08/14/2014 MPTAC review. Updated Description, Rationale, Background, References and Websites for Additional Information sections.
Revised 05/15/2014 MPTAC review. Clarified medically necessary statement and added an investigational and not medically necessary statement for hybrid cochlear implants. Updated Description, Rationale, Background, Definitions, Coding, References, and Websites for Additional Information sections.
Reviewed 05/09/2013 MPTAC review. Updated Rationale, Background, References, and Websites for Additional Information. Deleted Index section.
Reviewed 05/10/2012 MPTAC review. Updated Rationale, Background, References and Websites for Additional Information.
Revised 05/19/2011 MPTAC review. Revised medically necessary Position Statements: 1) Cochlear Implants, removed criterion "auditory cranial nerve can be stimulated" and 2) Auditory Brainstem Implants, reworded third criterion and removed (e.g. neurofibromatosis or von Recklinghausen's disease). Updated Rationale, Background, Definitions, Coding, References, and Websites for Additional Information.
Revised 11/18/2010 MPTAC review. Revised Description/Scope to 1) address cochlear implants, auditory brainstem implants, and replacement or upgrade of speech processor and controller components, and 2) state document does not address replacement parts other than those specified in the Position Statements. Revised medically necessary and not medically necessary Position Statements, focusing on 1) upgrade to or replacement of an existing external speech processor, controller or speech processor and controller (integrated system) for cochlear implants; and 2) upgrade to or replacement of an existing external sound processor, remote assistant, or both components for auditory brainstem implants. Reformatted Definitions. Updated Coding and References.
Revised 05/13/2010 MPTAC review. Revised medically necessary Position Statement for cochlear implants, by removing age limits of "12 months of age or older." Clarified medically necessary Position Statement for auditory brainstem implants. Revised Position Statements for medically necessary and not medically necessary criteria for replacement parts and upgrades to existing external components for cochlear implants and auditory brainstem implants. Updated Background, FDA Approval Table, Definitions, Coding and References. Added Websites for Additional Information.
  01/01/2010 Updated Coding section with 01/01/2010 HCPCS changes.
Reviewed 05/21/2009 MPTAC review. Updated Rationale and References.
Reviewed 05/15/2008 MPTAC review. Reformatted Rationale and Background sections. Updated Background and References to include CDC and FDA medical device safety notification concerning the increased risk of meningitis and the importance of vaccination in cochlear implant recipients.
  02/21/2008 The phrase "investigational/not medically necessary" was clarified to read "investigational and not medically necessary." This change was approved at the November 29, 2007 MPTAC meeting.
  10/01/2007 Updated Coding section with 10/01/2007 ICD-9 changes.
Reviewed 05/17/2007 MPTAC review. Rationale, Background, Definitions and References updated.
  01/01/2007 Updated Coding section with 01/01/2007 CPT/HCPCS changes.
Revised 07/25/2006 MPTAC review. Revision based on addition of MN criteria for bilateral cochlear implants. Expanded Rationale and Background sections. References and Coding updated.

 

01/01/2006 Updated Coding section with 01/01/2006 CPT/HCPCS changes

 

11/17/2005 Added reference for Centers for Medicare and Medicaid Services (CMS) – National Coverage Determination (NCD).
Revised 07/14/2005 MPTAC review. Revision based on Pre-merger Anthem and Pre-merger WellPoint Harmonization.
Pre-Merger Organizations

Last Review Date

Document Number

Title

Anthem, Inc.

04/28/2005

SURG.00014 Cochlear Implants and Auditory Brainstem Implants
WellPoint Health Networks, Inc.

04/28/2005

3.03.21  Cochlear Implants
 

04/28/2005

3.03.22 Auditory Brainstem Implants